Please assess the completion status of the following clinical trial:

Trial Title: Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~Healthy male subjects

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- BI 10773 25 mg (Type: EXPERIMENTAL): 1 tablet 25 mg BI 10773 qd for 5 days
- BI 10773 25 mg + Warfarin 25 mg (Type: EXPERIMENTAL): 1 tablet 25 mg BI 10773 qd for 7 days plus 5 tablets 5 mg warfarin single dose
- Warfarin 25 mg (Type: ACTIVE_COMPARATOR): 5 tablets 5 mg warfarin single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).